Sumitomo Dainippon Pharma Annual Report 2017
96/102

Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Millions of yenThousands ofU.S. dollars201620172017Sales to customers ¥ 360,92442,282 ¥ 403,206 ¥ 367,928 43,711 ¥ 411,639PharmaceuticalsOther productsTotal¥ 190,156181,085 31,965¥ 403,206 ¥ 186,354193,70631,579 ¥ 411,639JapanU.S.Other regionsTotalNet sales $ 440,82176,19712,027 $ 529,045 ¥ 51,8528,5131,460 ¥ 61,825 ¥ 49,3728,5341,348 ¥ 59,254JapanU.S.Other regions TotalProperty, plant and equipmentGeographical segment information for the Group for the years ended March 31, 2017 and 2016 were as follows:Sales information by major customer for the Group for the years ended March 31, 2017 and 2016 were as follows: $ 625,027 442,804408,786Name of major customer and related segment ¥ 62,474 47,77842,168 ¥ 70,003 49,59445,784McKesson Corporation / North AmericaCardinal Health Inc. / North AmericaAmerisourceBergen Corporation/ North AmericaNet sales5) Other informationSales information by product or service for the Group for the years ended March 31, 2017 and 2016 were as follows: $ 3,285,071 390,277 $ 3,675,348 $ 1,663,875 1,729,518 281,955 $ 3,675,348 $ 68,4642,646,1252,473 $ 2,717,062 ¥ 8,792147,241548 ¥ 156,581 ¥ 7,668296,366277 ¥ 304,311JapanU.S.Other regions TotalIntangible assetsNotes to Consolidated Financial StatementsSumitomo Dainippon Pharma Co., Ltd. and Consolidated SubsidiariesYears Ended March 31, 2017 and 2016Financial SectionSumitomo Dainippon Pharma Co., Ltd. Annual Report 201795

元のページ  ../index.html#96

このブックを見る